Arformoterol

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]

Arformoterol
Clinical data
Trade namesBrovana
Other namesArformoterol tartrate (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa602023
License data
Routes of
administration
Inhalation
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Protein binding52–65%
Elimination half-life26 hours
Identifiers
IUPAC name
  • N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H24N2O4
Molar mass344.411 g·mol−1
InChI
  • InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 Y
  • Key:BPZSYCZIITTYBL-YJYMSZOUSA-N Y
 NY (what is this?)  (verify)

It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.[1] It was approved for medical use in the United States in October 2006.[1] It is available as a generic medicine.[3]

Medical uses

Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).[1]

References

  1. "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.
  2. Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810.
  3. "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration. Retrieved 17 May 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.